ARE WE PREPARED FOR PrEP? THE CHALLENGES OF IMPLEMENTING PROVEN BIOMEDICAL PREVENTION TECHNOLOGIES

IAS Industry Liaison Forum, 8am-10am, Sunday 22 July 2007, Parkside Ballroom B, Sydney Convention and Exhibition Centre, Darling Drive, Darling Harbour, Sydney
Programme Chairs

Elly Katabira
IAS-ILF Co-Chair and Makerere University, Uganda

Joep Lange
IAS ILF Co-Chair and AMC Center for Poverty-related Communicable Diseases, the Netherlands

Programme

8.00am Welcome, introductions and programme objectives
Elly Katabira

8.10am What is the status of our preparation for PrEP implementation?
Dawn Smith, US Centers for Disease Control and Prevention, USA

8.25am How much could PrEP help? Modeling potential impact on the epidemic
Sally Blower, University of California Los Angeles, USA

8.40am Lessons learned from ARV rollout programmes
Sheila Tlou, Ministry of Health, Botswana

9.00am Discussion facilitated by Joep Lange

9.15am Roles and responsibilities in PrEP implementation
Panel discussion facilitated by Pedro Cahn, IAS President and Huesped Fundación, Argentina

Discussants

Donor perspectives: Renee Ridzon, Bill & Melinda Gates Foundation, USA

Normative guidelines: Cate Hankins, UNAIDS

Civil society perspectives: Morenike Ukpong, Nigeria HIV. Vaccine and Microbicide Advocacy Group, Nigeria

Industry responsibilities: Wim Parys, Tibotec, Belgium

9.30am Meeting close

Pre-exposure prophylaxis (PrEP) involving antiretroviral agents demonstrate great potential in reducing HIV transmission. However, even if proven effective, the challenges of delivering PrEP remain formidable. Informed policy response, effective communication and advocacy as well as collaborations with potential funders will be paramount in the successful implementation of PrEP.